Phagocytosis News and Research

RSS

Insight into molecular basis of Enhanced S-Cone Syndrome

A new research report published in The FASEB Journal will help ophthalmologists and scientists better understand a rare genetic disease that causes increased susceptibility to blue light, night blindness, and decreased vision called Enhanced S-Cone Syndrome or Goldman-Favre Syndrome.

2 Sep 2011

Scientists discover how immune cells recognize invading pathogens in the body

Scientists at Cedars-Sinai Medical Center have discovered how a molecular receptor on the surface of white blood cells identifies when invading fungi have established direct contact with the cell surface and pose an infectious threat.

30 Apr 2011

Researchers develop non-steroid based strategy for patients with COPD

Researchers at the Johns Hopkins Bloomberg School of Public Health have developed a non-steroid based strategy for improving the lung's innate immune defense and decreasing inflammation that can be a problem for patients with chronic obstructive pulmonary disease.

15 Apr 2011

Dr Russell Wallis, Reader and RCUK Academic Fellow to give Frank May Prize Lecture 2010

The Frank May Prize Lecture 2010, entitled 'Fishing for Complement: innate targeting of microbial pathogens', will be given by Dr Russell Wallis, Reader and RCUK Academic Fellow in the Department of Infection, Immunity and Inflammation, and Department of Biochemistry.

5 Mar 2011

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

The interest in the biological effects of non-ionizing Electro Magnetic Fields (EMFs) and Static Magnetic Fields (SMFs) on the whole organism, as well on cellular systems, has noticeably increased in recent years in consideration of their increased production (from the generation and transmission of electricity, to domestic appliances and industrial equipment, to telecommunications and broadcasting) and the possible health risk for humans.

4 Dec 2010

Trillium presents results from cancer stem cell program at ASH Annual Meeting

Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that preliminary results from its cancer stem cell program, targeting the CD47 protein, will be reported in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida, December 4-7, 2010.

2 Dec 2010

WILD, Sterling Technology announce partnership for Immunel, Tegricel products

WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.

20 Oct 2010

GBS pathogen suppresses immune cell function in newborn infants: Research

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

27 Sep 2010

Research marks new direction to treat Pneumocystis, inflammatory diseases

A drug to treat inflammation plays a surprising role reducing the level of infection caused by an opportunistic bug that is deadly for AIDS and cancer patients and others with weakened immune systems.

20 Aug 2010

Indispensable role of Mindin in innate and adaptive immunity

Mindin has an indispensable role in both innate and adaptive immunity. A research group in China investigated regulation of mindin expression and the signaling pathway involved. mRNA expression of mindin was upregulated during dextran sulfate sodium induced mouse intestinal inflammation. Stimulation with CpG-ODN (a known TLR-9 ligand) induced upregulation of mindin expression in RAW 264.7 cells and significantly increased the NF-κB-luciferase activity in vitro.

31 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Nitric oxide may play key role in the pathogenesis of neonatal meningitis

Current research suggests that nitric oxide may play a role in the pathogenesis of neonatal meningitis. The related report by Mittal et al, "Inhibition of inducible nitric oxide controls pathogen load and brain damage by enhancing phagocytosis of Escherichia coli K1 in neonatal meningitis," appears in the March 2010 issue of The American Journal of Pathology.

24 Feb 2010

Baker's yeast promising against cancer

A researcher at Charles Drew University of Medicine and Science is investigating the potential use of non-pathogenic baker's yeast as a promising, natural therapy for cancer.

3 Feb 2010

Doctoral candidate sheds new light on the biology of Leishmania parasites

Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated.

24 Oct 2009

Brain inflammation not linked to Alzheimer's disease

In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.

23 Oct 2009

PIKAMAB obtains U.S. patent rights to develop theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.

15 Oct 2009

Pathogenic microbes can suppress immune system in newborns

2 Sep 2009

Gene therapy for retinitis pigmentosa

An international team of scientists and clinicians from the United States and Saudi Arabia are working to develop gene therapy for treating a rare, hereditary retinal disease.

31 Jul 2009

Xencor and CSL Limited establish antibody optimization collaboration

Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

23 Feb 2009